AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

NCT06106945 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

226

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: AZD0305
DRUG: Elranatamab
DRUG: Pomalidomide
DRUG: Dexamethasone

Sponsor

AstraZeneca